Skip to main content
PMC home page
Molecular Pathology : MP logoLink to Molecular Pathology : MP
. 1997 Feb;50(1):18–20. doi: 10.1136/mp.50.1.18

p53 gene mutations in multiple myeloma.

R G Owen 1, S A Davis 1, J Randerson 1, A C Rawstron 1, F Davies 1, J A Child 1, A S Jack 1, G J Morgan 1
PMCID: PMC379574  PMID: 9208809

Abstract

AIM: To assess whether p53 gene mutation is important in the pathogenesis and progression of multiple myeloma. METHODS: Thirty eight DNA samples (derived predominantly from bone marrow) obtained from 31 patients with multiple myeloma were examined for mutations in p53 exons 5-9 by polymerase chain reaction single strand conformation polymorphism. Twenty three samples were analysed at the time of diagnosis (one patient had plasma cell leukaemia), three in plateau phase, and 12 at relapse (one plasma cell leukaemia and one extramedullary relapse). RESULTS: One p53 mutation was detected in this group of patients (3.2%). This was seen in the diagnostic bone marrow sample of a 35 year old man with stage IIA disease and occurred in exon 6 as a result of a silent A to G transition at codon 213 (CGA-->CGG), a polymorphism that has been reported in about 3% of breast and lung tumours. CONCLUSIONS: p53 gene mutations are rare events in multiple myeloma and would seem to be of limited value as a prognostic factor.

Full text

PDF
20

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baker S. J., Fearon E. R., Nigro J. M., Hamilton S. R., Preisinger A. C., Jessup J. M., vanTuinen P., Ledbetter D. H., Barker D. F., Nakamura Y. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science. 1989 Apr 14;244(4901):217–221. doi: 10.1126/science.2649981. [DOI] [PubMed] [Google Scholar]
  2. Carbone D., Chiba I., Mitsudomi T. Polymorphism at codon 213 within the p53 gene. Oncogene. 1991 Sep;6(9):1691–1692. [PubMed] [Google Scholar]
  3. Corradini P., Inghirami G., Astolfi M., Ladetto M., Voena C., Ballerini P., Gu W., Nilsson K., Knowles D. M., Boccadoro M. Inactivation of tumor suppressor genes, p53 and Rb1, in plasma cell dyscrasias. Leukemia. 1994 May;8(5):758–767. [PubMed] [Google Scholar]
  4. Hollstein M., Sidransky D., Vogelstein B., Harris C. C. p53 mutations in human cancers. Science. 1991 Jul 5;253(5015):49–53. doi: 10.1126/science.1905840. [DOI] [PubMed] [Google Scholar]
  5. Imamura J., Miyoshi I., Koeffler H. P. p53 in hematologic malignancies. Blood. 1994 Oct 15;84(8):2412–2421. [PubMed] [Google Scholar]
  6. Kyle R. A., Greipp P. R. Smoldering multiple myeloma. N Engl J Med. 1980 Jun 12;302(24):1347–1349. doi: 10.1056/NEJM198006123022405. [DOI] [PubMed] [Google Scholar]
  7. Mazars G. R., Portier M., Zhang X. G., Jourdan M., Bataille R., Theillet C., Klein B. Mutations of the p53 gene in human myeloma cell lines. Oncogene. 1992 May;7(5):1015–1018. [PubMed] [Google Scholar]
  8. Neri A., Baldini L., Trecca D., Cro L., Polli E., Maiolo A. T. p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy. Blood. 1993 Jan 1;81(1):128–135. [PubMed] [Google Scholar]
  9. Nigro J. M., Baker S. J., Preisinger A. C., Jessup J. M., Hostetter R., Cleary K., Bigner S. H., Davidson N., Baylin S., Devilee P. Mutations in the p53 gene occur in diverse human tumour types. Nature. 1989 Dec 7;342(6250):705–708. doi: 10.1038/342705a0. [DOI] [PubMed] [Google Scholar]
  10. Portier M., Molès J. P., Mazars G. R., Jeanteur P., Bataille R., Klein B., Theillet C. p53 and RAS gene mutations in multiple myeloma. Oncogene. 1992 Dec;7(12):2539–2543. [PubMed] [Google Scholar]
  11. Preudhomme C., Facon T., Zandecki M., Vanrumbeke M., Laï J. L., Nataf E., Loucheux-Lefebvre M. H., Kerckaert J. P., Fenaux P. Rare occurrence of P53 gene mutations in multiple myeloma. Br J Haematol. 1992 Jul;81(3):440–443. doi: 10.1111/j.1365-2141.1992.tb08253.x. [DOI] [PubMed] [Google Scholar]
  12. Prosser J., Thompson A. M., Cranston G., Evans H. J. Evidence that p53 behaves as a tumour suppressor gene in sporadic breast tumours. Oncogene. 1990 Oct;5(10):1573–1579. [PubMed] [Google Scholar]
  13. Takahashi T., Nau M. M., Chiba I., Birrer M. J., Rosenberg R. K., Vinocour M., Levitt M., Pass H., Gazdar A. F., Minna J. D. p53: a frequent target for genetic abnormalities in lung cancer. Science. 1989 Oct 27;246(4929):491–494. doi: 10.1126/science.2554494. [DOI] [PubMed] [Google Scholar]
  14. Willems P. M., Kuypers A. W., Meijerink J. P., Holdrinet R. S., Mensink E. J. Sporadic mutations of the p53 gene in multiple myeloma and no evidence for germline mutations in three familial multiple myeloma pedigrees. Leukemia. 1993 Jul;7(7):986–991. [PubMed] [Google Scholar]
  15. Yasuga Y., Hirosawa S., Yamamoto K., Tomiyama J., Nagata K., Aokia N. N-ras and p53 gene mutations are very rare events in multiple myeloma. Int J Hematol. 1995 Aug;62(2):91–97. doi: 10.1016/0925-5710(95)00394-8. [DOI] [PubMed] [Google Scholar]

Articles from Molecular Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES